expanded activated haploidentical natural killer cells (National University Hospital, Singapore)

This experimental cell therapy consists of allogeneic, haploidentical natural killer (NK) cells that are expanded and activated ex vivo. Developed by the National University Hospital, Singapore, the production process involves co-culturing donor-derived NK cells with an irradiated K562 feeder cell line genetically modified to express membrane-bound interleukin-15 (IL-15) and 4-1BB ligand (CD137L). This specific stimulation promotes the selective proliferation and functional maturation of the NK cells, enhancing their natural cytotoxic capacity against malignant cells. To ensure safety and prevent graft-versus-host disease (GVHD), the final product is depleted of T cells prior to administration. The therapy is primarily being investigated for the treatment of high-risk hematologic malignancies, including acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), and myelodysplastic syndrome (MDS), particularly in patients with persistent minimal residual disease.

Other names

NK cellsexpanded activated NK cellshaploidentical NK cellsallogeneic NK cells